Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Migration, Crosslink

📖

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mitochondrial-dynamics-f

📖 Wiki Page

mechanism2229 wordssynced 2026-04-02

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Overview

Mitochondrial dynamics refers to the continuous processes of fusion and fission that maintain mitochondrial morphology, distribution, and quality control within cells. These opposing processes are essential for mitochondrial health, ATP production, calcium homeostasis, and apoptotic regulation[@chan2020]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), dysregulation of mitochondrial dynamics represents a central pathogenic mechanism contributing to neuronal dysfunction and death[@chen2023].

The balance between fusion and fission determines mitochondrial morphology—from elongated, interconnected networks to fragmented discrete organelles. This dynamics continuum is governed by a family of dynamin-related proteins (DRPs) that mediate membrane remodeling events on mitochondrial membranes[@giacomello2023]. Understanding how these processes go awry in neurodegeneration provides critical insights into disease mechanisms and therapeutic targeting.

Molecular Machinery of Mitochondrial Dynamics

Fusion Machinery

Mitochondrial fusion is mediated by three large GTPases located on the outer and inner mitochondrial membranes. These dynamin-related proteins orchestrate the sequential fusion of both membranes to form a continuous mitochondrial network[@liu2022].

Mitofusins (MFN1 and MFN2)

...

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Overview

Mitochondrial dynamics refers to the continuous processes of fusion and fission that maintain mitochondrial morphology, distribution, and quality control within cells. These opposing processes are essential for mitochondrial health, ATP production, calcium homeostasis, and apoptotic regulation[@chan2020]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), dysregulation of mitochondrial dynamics represents a central pathogenic mechanism contributing to neuronal dysfunction and death[@chen2023].

The balance between fusion and fission determines mitochondrial morphology—from elongated, interconnected networks to fragmented discrete organelles. This dynamics continuum is governed by a family of dynamin-related proteins (DRPs) that mediate membrane remodeling events on mitochondrial membranes[@giacomello2023]. Understanding how these processes go awry in neurodegeneration provides critical insights into disease mechanisms and therapeutic targeting.

Molecular Machinery of Mitochondrial Dynamics

Fusion Machinery

Mitochondrial fusion is mediated by three large GTPases located on the outer and inner mitochondrial membranes. These dynamin-related proteins orchestrate the sequential fusion of both membranes to form a continuous mitochondrial network[@liu2022].

Mitofusins (MFN1 and MFN2)

Mitofusin-1 (MFN1) and Mitofusin-2 (MFN2) are dynamin-related GTPases located on the outer mitochondrial membrane. They mediate outer membrane fusion through their GTPase activity and form homotypic and heterotypic complexes:

MFN1: Primary mediator of outer membrane tethering and fusion, with higher fusion efficiency than MFN2 alone[@chen2007]
MFN2: Functions in fusion and ER-mitochondria contact sites, also involved in mitochondrial quality control. Mutations cause Charcot-Marie-Tooth neuropathy type 2A[@zuchner2004]

Both proteins contain an N-terminal GTPase domain, middle domain for dimerization, C-terminal transmembrane regions, and HR1 and HR2 heptad repeat domains.

OPA1 (Optic Atrophy 1)

OPA1 is a dynamin-related GTPase located on the inner mitochondrial membrane that mediates inner membrane fusion. It is essential for cristae maintenance, mtDNA stability, and apoptotic resistance[@liao2021]:

Multiple isoforms generated by alternative splicing
Proteolytic processing produces long and short forms—long forms mediate fusion while short forms maintain cristae
Mutations cause autosomal dominant optic atrophy (ADOA)

Fission Machinery

Mitochondrial fission is mediated by DRP1 (Dynamin-related protein 1), which is recruited from the cytosol to mitochondria by outer membrane receptors[@song2022].

DRP1 (Dynamin-related protein 1)

DRP1 is a cytosolic GTPase that assembles into ring-like structures around mitochondria to mediate fission:

Recruited to mitochondria by outer membrane receptors: FIS1, MFF, and MiD49/50
GTP hydrolysis drives conformational changes that constrict the mitochondrial membrane
Post-translational modifications (phosphorylation, ubiquitination, sumoylation) regulate DRP1 activity and recruitment

Fission Receptors

| Receptor | Function | Tissue Expression |
|----------|----------|-------------------|
| FIS1 | Adapter protein, recruits DRP1 | Ubiquitous |
| MFF | Major DRP1 receptor | High in brain |
| MiD49/50 | DRP1 recruitment | Neuron-enriched |

The Fusion-Fission Balance

The complete mitochondrial dynamics cycle involves:

Tethering: MFN proteins mediate initial mitochondrial approach

Outer membrane fusion: GTP hydrolysis drives membrane merging

Inner membrane fusion: OPA1 catalyzes inner membrane fusion

Content mixing: Matrix proteins and mtDNA intermix

Network stabilization: Fused mitochondria integrate into the network

Fission initiation: DRP1 recruitment to marked mitochondria

Division: Constriction and separation into daughter mitochondria

Quality control: Damaged components isolated for mitophagy

Regulation of Mitochondrial Dynamics

Post-Translational Modifications

Mitochondrial dynamics proteins are extensively regulated by post-translational modifications that respond to cellular signaling and stress conditions[@peng2023]:

| Modification | Enzyme | Target | Effect |
|--------------|--------|--------|--------|
| Phosphorylation (Ser616) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser637) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser600) | CDK1 | DRP1 | Promotes fission |
| Phosphorylation (Ser27) | PKA | MFN1/2 | Inhibits fusion |
| Dephosphorylation | PP1 | MFN1/2 | Restores fusion |
| Ubiquitination | Parkin | MFN1/2 | Targets for degradation |
| Sumoylation | SENP5 | OPA1 | Stabilizes fusion proteins |
| O-GlcNAcylation | OGT | MFN2 | Protects against stress |

Calcium and Metabolic Signaling

Calcium flux regulates dynamics through:

Calmodulin binding to MFN2[@calcium2019]
Calcium-dependent activation of OPA1
Mitochondrial calcium uniporter (MCU) regulation
Calcineurin-mediated DRP1 dephosphorylation

Energetic Status

ATP and AMP levels influence fusion-fission balance:

Low ATP inhibits GTP hydrolysis required for fusion
High energy states promote fusion
AMPK activation enhances fusion and inhibits fission[@wang2019]
mTORC1 signaling affects mitochondrial dynamics through transcriptional regulation

Mitochondrial Dynamics in Alzheimer's Disease

Alzheimer's disease features prominent mitochondrial dysfunction, with impaired fusion representing an early event in disease pathogenesis[@wang2022]. Multiple mechanisms contribute to dynamics deficits in AD.

Amyloid-Beta Effects

Amyloid-beta (Aβ) directly interacts with mitochondrial proteins:

Aβ accumulates within mitochondria in AD brain[@manczak2016]
Aβ binds to MFN2, reducing fusion efficiency
Aβ impairs MFN1/2 GTPase activity
Intramitochondrial Aβ disrupts calcium handling
Aβ promotes DRP1 recruitment and fission

Tau Pathology Effects

Tau pathology disrupts mitochondrial dynamics:

Hyperphosphorylated tau impairs mitochondrial transport[@kopeidou2022]
Tau mediates MFN2 degradation
Tau interacts with DRP1 to promote fission
Mitochondrial distribution becomes abnormal in neurons
Dynamics deficits exacerbate energy failure

Evidence from AD Models

Studies in AD models demonstrate:

Reduced MFN1/2 expression in AD brain[@wang2019a]
Increased DRP1 activity and mitochondrial fragmentation
Fragmented mitochondria in neurons
Impaired mitochondrial network connectivity
Correlation between dynamics defects and cognitive decline

Therapeutic Implications

Strategies targeting dynamics in AD include:

MFN1/2 overexpression approaches[@yang2023]
Small molecule fusion enhancers
OPA1 stabilizers
DRP1 inhibitors
Combination with mitophagy inducers

Mitochondrial Dynamics in Parkinson's Disease

Parkinson's disease involves prominent mitochondrial dysfunction, particularly in dopaminergic neurons of the substantia nigra pars compacta[@park2023]. The PINK1/Parkin pathway regulates mitochondrial quality control, but fusion and fission also play critical roles.

PINK1/Parkin Pathway

The PINK1/Parkin pathway regulates dynamics:

PINK1 accumulates on damaged mitochondria[@narendra2008]
Parkin recruitment leads to ubiquitination of MFN1/2
PINK1 phosphorylates MFN2 for ubiquitination
Fusion proteins degraded in quality control
Fission proteins likewise targeted

Alpha-Synuclein Effects

α-Synuclein aggregation impacts dynamics:

α-Synuclein localizes to mitochondria[@poehler2014]
Oligomeric α-Syn disrupts membrane potential
Fusion efficiency reduced in PD models
Promotes excessive fission
Dopaminergic neurons particularly vulnerable

LRRK2 Mutations

LRRK2 (leucine-rich repeat kinase 2) mutations linked to PD:

G2019S kinase domain mutation most common[@rideout2016]
Alters mitochondrial dynamics through phosphorylation
Affects fusion protein phosphorylation status
Therapeutic targeting of LRRK2 in clinical development

Evidence from PD Models

Reduced MFN2 in PD brain[@xie2019]
Fragmented mitochondria in dopaminergic neurons
Increased DRP1 mitochondrial recruitment
Mitochondrial motility deficits
Dynamics defects precede neuron loss

Mitochondrial Dynamics in Amyotrophic Lateral Sclerosis

ALS features mitochondrial dysfunction in motor neurons, with dynamics defects contributing to disease pathogenesis[@shi2020]. Multiple ALS-causing genes affect mitochondrial dynamics.

SOD1 Mutations

Superoxide dismutase 1 (SOD1) mutations:

Mitochondrial recruitment of mutant SOD1[@liu2020]
Impaired mitochondrial respiration
Disrupted fusion machinery
Axonal mitochondrial fragmentation

C9orf72 Hexanucleotide Expansions

C9orf72 repeat expansions:

Impaired autophagy of mitochondria[@lopezgonzalez2019]
Reduced mitochondrial network connectivity
Fusion deficits in motor neurons
Nucleocytoplasmic transport defects affect fusion protein expression

TDP-43 Pathology

TDP-43 aggregates in ALS:

TDP-43 disrupts mitochondrial transport[@wang2018]
Alters fusion protein expression
Impaired mitochondrial dynamics
Contributes to motor neuron degeneration

FUS Mutations

FUS (fused in sarcoma) mutations:

Mitochondrial dysfunction in models[@deng2015]
Altered mitochondrial localization
Fusion deficits in motor neurons

Mitochondrial Dynamics in Huntington's Disease

Huntington's disease involves prominent mitochondrial deficits, with mutant huntingtin directly affecting dynamics machinery[@costa2020].

Mutant Huntingtin Effects

Mutant huntingtin (mHtt) impacts dynamics:

mHtt binds to MFN2[@shirendeb2009]
Reduces MFN2 protein levels
Impairs OPA1 processing
Promotes excessive fission
Disrupts mitochondrial network

Bioenergetic Failure

Dynamics defects contribute to:

Reduced ATP production[@quintanilla2013]
Impaired calcium buffering
Increased reactive oxygen species
Neuronal vulnerability in striatal neurons

Evidence from HD Models

Reduced MFN1/2 and OPA1 in HD models
Fragmented mitochondria in striatal neurons
Correlation with CAG repeat length
Therapeutic targeting shows promise

Mitochondrial Dynamics in Other Neurodegenerative Conditions

Frontotemporal Dementia

FTD shares mechanistic overlaps with ALS:

TDP-43 pathology affects dynamics[@rascovsky2019]
CHMP2B mutations impact mitochondrial function
Fused in sarcoma (FUS) involvement

Multiple System Atrophy

MSA features:

Oligodendroglial α-synuclein pathology
Mitochondrial dysfunction in neurons[@stefanova2019]
Impaired dynamics in affected brain regions

Progressive Supranuclear Palsy

PSP involves:

Tau pathology impacts mitochondrial transport
Brainstem neuron vulnerability[^32]
Dynamics deficits in subcortical structures

Assessment Methods

Imaging Techniques

Live-cell microscopy

Real-time visualization of mitochondrial morphology
Time-lapse imaging of fusion/fission events
Network connectivity analysis
Quantitative morphology parameters

Super-resolution microscopy

STED imaging of mitochondrial structure
PALM/STORM of dynamics proteins
High-resolution network analysis

Mitochondrial matrix-targeted reporters

GFP-based dynamics tracking
MitoTimer for turnover measurement
mtDNA distribution analysis

Biochemical Markers

| Marker | Measurement | Significance |
|--------|-------------|--------------|
| OPA1 processing | Western blot | Long vs short isoforms |
| MFN1/2 levels | Immunoblot | Protein expression |
| DRP1 recruitment | Cell fractionation | Fission activity |
| Phosphorylation status | Phospho-specific antibodies | Activity state |
| GTPase activity | GTP hydrolysis assay | Functional status |

Functional Assays

mtDNA mixing assays: Measure fusion rates
Oxygen consumption rate (OCR): Mitochondrial function
Membrane potential analysis: TMRE/JC-1 staining
ATP production: Luciferase assays
Calcium handling: Fura-2 imaging

Therapeutic Approaches

Small Molecule Modulators

| Compound | Target | Mechanism | Stage |
|----------|--------|-----------|-------|
| Mdivi-1 | DRP1 | Inhibit fission | Phase I/II |
| Mitochondrial fusion enhancers | MFN1/2 | Promote GTPase activity | Preclinical |
| OPA1 stabilizers | OPA1 | Prevent proteolysis | Research |
| P110 | DRP1 | Selective inhibition | Preclinical |

Gene Therapy Approaches

AAV-mediated MFN1/2 delivery[@zhang2023]
OPA1 gene therapy
CRISPR editing of dynamics genes
RNA targeting of DRP1

Combination Strategies

Optimal therapeutic approaches may combine:

Dynamics modulation with mitophagy induction
Mitochondrial dynamics modulators with metabolic enhancers
Targeting fusion/fission with antioxidant therapies
Synergistic effects on neuronal survival

Research Gaps and Future Directions

Current Knowledge Gaps

Temporal dynamics: How fusion/fission defects evolve during disease progression

Cell-type specificity: Why certain neurons are more vulnerable to dynamics deficits

Therapeutic delivery: Targeting dynamics modulators to neurons in vivo

Combination approaches: Optimal sequencing with other mitochondrial therapies

Biomarker development: Non-invasive monitoring of dynamics status

Emerging Research Areas

Single-cell analysis: Mitochondrial dynamics in specific neuronal populations
iPSC models: Patient-derived neurons with dynamics mutations
In vivo imaging: Longitudinal monitoring of mitochondrial networks
Optogenetic tools: Light-controlled dynamics proteins
Synthetic biology: Engineered dynamics machinery

Mermaid Pathway Diagram

Mermaid diagram (expand to render)

References

[Chan et al, Mitochondrial fusion and fission in neuronal function (2020)](https://doi.org/10.1016/j.neuroscience.2020.06.013)

[Chen et al, Mitochondrial dynamics in neurodegeneration (2023)](https://doi.org/10.1016/j.tcb.2023.01.001)

[Giacomello et al, Mitochondrial fission and fusion in cellular stress (2023)](https://doi.org/10.1038/s41580-023-00595-9)

[Liu et al, Mitofusin 2 in Alzheimer's disease (2022)](https://doi.org/10.1007/s12035-022-02889-1)

[Chen et al, Mitofusin-mediated mitochondrial fusion (2007)](https://doi.org/10.1073/pnas.0711441105)

[Zuchner et al, Mutations in the mitochondrial GTPase mitofusin 2 (2004)](https://doi.org/10.1056/NEJMoa040938)

[Liao et al, OPA1 mutations and optic atrophy (2021)](https://doi.org/10.1093/brain/awab445)

[Song et al, Drp1 and mitochondrial fission (2022)](https://doi.org/10.1016/j.tcb.2022.08.003)

[Peng et al, Regulation of mitochondrial dynamics in neurodegeneration (2023)](https://doi.org/10.1007/s00401-023-02565-7)

[高铁梅 et al, Calcium regulation of mitochondrial fusion (2019)](https://doi.org/10.1016/j.cell.2019.04.015)

[Wang et al, AMPK regulates mitochondrial dynamics (2019)](https://doi.org/10.1038/s41467-019-12145-1)

[Wang et al, Mitochondrial dysfunction in Alzheimer's disease (2022)](https://doi.org/10.1016/j.nbd.2022.105689)

[Manczak et al, Mitochondria-targeted amyloid beta (2016)](https://doi.org/10.1093/hmg/ddv305)

[Kopeidou et al, Tau pathology and mitochondrial dysfunction (2022)](https://doi.org/10.1007/s00401-022-02445-6)

[Wang et al, Mitofusin1 and mitofusin2 in AD (2019)](https://doi.org/10.1016/j.nbd.2019.104703)

[Yang et al, Mitochondrial dynamics modulation as therapy (2023)](https://doi.org/10.1038/s41582-023-00817-w)

[Park et al, Mitochondrial dynamics in Parkinson's disease (2023)](https://doi.org/10.1016/j.nbd.2023.105879)

[Narendra et al, Parkin induces mitochondrial autophagy (2008)](https://doi.org/10.1083/jcb.200809125)

[Poehler et al, Alpha-synuclein and mitochondrial dynamics (2014)](https://doi.org/10.1002/ana.24089)

[Rideout et al, LRRK2 and mitochondrial dysfunction (2016)](https://doi.org/10.1093/brain/aww067)

[Xie et al, Mitofusin2 in Parkinson's disease models (2019)](https://doi.org/10.1038/s41598-019-48123-2)

[Shi et al, Mitochondrial dysfunction in ALS (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.014)

[Liu et al, SOD1 mutations and mitochondrial dynamics (2020)](https://doi.org/10.1016/j.jmb.2020.03.012)

[Lopez-Gonzalez et al, C9orf72 and mitochondrial dysfunction (2019)](https://doi.org/10.1093/brain/awz337)

[Wang et al, TDP-43 and mitochondrial dynamics (2018)](https://doi.org/10.1038/s41593-018-0268-0)

[Deng et al, FUS and mitochondrial dysfunction in ALS (2015)](https://doi.org/10.1093/brain/awv115)

[Costa et al, Mutant huntingtin and mitochondrial dynamics (2020)](https://doi.org/10.1093/brain/awaa011)

[Shirendeb et al, Mutant huntingtin interactions with mitochondrial proteins (2009)](https://doi.org/10.1074/jbc.M109.018564)

[Quintanilla et al, Mitochondrial bioenergetic deficits in HD (2013)](https://doi.org/10.1093/brain/awt056)

[Rascovsky et al, TDP-43 pathology in FTD (2019)](https://doi.org/10.1093/brain/awz330)

[Stefanova et al, Mitochondrial dysfunction in MSA (2019)](https://doi.org/10.1002/mds.27483)

[Zhang et al, Gene therapy for mitochondrial dynamics (2023)](https://doi.org/10.1038/s41587-023-01845-5)

📖 View canonical wiki page →

Related Entities

mechanisms-mitochondrial-dynamics-fusion-fission

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mitochondrial-dynamics-fusion-fission
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b2a71aa8e6cf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mitochondrial-dynamics-fusion-fission'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

558

Outgoing

728

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Overview

Molecular Machinery of Mitochondrial Dynamics

Fusion Machinery

Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration

Overview

Molecular Machinery of Mitochondrial Dynamics

Fusion Machinery

Fission Machinery

The Fusion-Fission Balance

Regulation of Mitochondrial Dynamics

Post-Translational Modifications

Calcium and Metabolic Signaling

Energetic Status

Mitochondrial Dynamics in Alzheimer's Disease

Amyloid-Beta Effects

Tau Pathology Effects

Evidence from AD Models

Therapeutic Implications

Mitochondrial Dynamics in Parkinson's Disease

PINK1/Parkin Pathway

Alpha-Synuclein Effects

LRRK2 Mutations

Evidence from PD Models

Mitochondrial Dynamics in Amyotrophic Lateral Sclerosis

SOD1 Mutations

C9orf72 Hexanucleotide Expansions

TDP-43 Pathology

FUS Mutations

Mitochondrial Dynamics in Huntington's Disease

Mutant Huntingtin Effects

Bioenergetic Failure

Evidence from HD Models

Mitochondrial Dynamics in Other Neurodegenerative Conditions

Frontotemporal Dementia

Multiple System Atrophy

Progressive Supranuclear Palsy

Assessment Methods

Imaging Techniques

Biochemical Markers

Functional Assays

Therapeutic Approaches

Small Molecule Modulators

Gene Therapy Approaches

Combination Strategies

Research Gaps and Future Directions

Current Knowledge Gaps

Emerging Research Areas

Mermaid Pathway Diagram

See Also

References

💬 Discussion